NeurAxis, Inc. announced its financial results for the second quarter ended June 30, 2025, on August 12, 2025. The company reported a significant 46% year-over-year increase in revenues, reaching $894 thousand in 2Q25.
This revenue growth demonstrates continued commercial momentum for NeurAxis's neuromodulation therapies. The consistent increase in sales indicates growing adoption of its IB-Stim device and other products.
The company's ability to sustain strong revenue growth is a key indicator of its market penetration and the effectiveness of its commercialization strategy. This financial performance supports the company's long-term objectives.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.